D-0862-2020 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0862-2020 was initiated by Teva Pharmaceuticals USA on Feb 20, 2020 and is designated Class II. Reason for recall: Failed Dissolution Specifications: Low out of specification dissolution result observed during stability testing. The recall status is terminated (terminated Oct 6, 2020). Affected quantity: 3,695 bottles.

Recall details

Product Type
Drugs
Report Date
Mar 11, 2020
Initiation Date
Feb 20, 2020
Termination Date
Oct 6, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
3,695 bottles

Product description

Mesalamine Delayed-Release Tablets, USP, 1.2 gram, 120-count bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314; Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054; NDC 0591-2245-22.

Reason for recall

Failed Dissolution Specifications: Low out of specification dissolution result observed during stability testing.

Distribution pattern

Nationwide in the USA.

Code information

Lot #: 1342500A, Exp 10/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0862-2020
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0862-2020. Report a data issue: hello@regdatalab.com.